🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen, Pre-filled pen containing 2.16mL solution, subcutaneous injection

    Ferring Pharmaceuticals

    Idiopathic male infertility (including oligoasthenozoospermia).

    phase 2 small molecule active

    1 trial

  2. REZZAYO 200 mg powder for concentrate for solution for infusion

    Mundipharma Pty Limited

    Chronic pulmonary aspergillosis (CPA)

    phase 2 small molecule active

    1 trial

  3. RHB-104

    RedHill Biopharma

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  4. RIFAMPICIN , TEDIZOLID PHOSPHATE, ISONIAZID , ETHAMBUTOL , PYRAZINAMIDE , RIFAMPICIN, PYRAZINAMIDE AND ISONIAZID, LINEZOLID

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

  5. RILPIVIRINE , JNJ-16150108

    Xian-Janssen Pharmaceutical

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  6. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  7. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  8. ROT-TDS, Neupro 8 mg/24 h transdermal patch, Neupro 8 mg/24 h transdermal patch

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  9. RP-A501

    Rocket Pharmaceuticals B.V.

    Danon Disease

    phase 2 gene therapy active

    2 trials

  10. RP-L102

    Rocket Pharmaceuticals B.V.

    Fanconi Anemia Complementation Group A

    phase 2 mab active

    3 trials

  11. RP-L201

    Rocket Pharmaceuticals B.V.

    Leukocyte Adhesion Defect - Type I

    phase 2 mab completed

    2 trials

  12. RP-L301

    Rocket Pharmaceuticals B.V.

    Pyruvate Kinase Deficiency

    phase 2 mab on hold

    2 trials

  13. RP5063

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Acute Schizophrenia

    phase 2 small molecule completed

    1 trial

  14. RTA 408 Capsule, 10 mg, Skyclarys 50 mg hard capsules, RTA 408 Capsule, 2.5 mg, Skyclarys 50 mg hard capsules

    Lacuna Pharma Pty Ltd

    Friedreich's ataxia

    phase 2 small molecule active

    1 trial

  15. RTP-026 Placebo, RTP-026

    Lacuna Pharma Pty Ltd

    Patients with ST-Elevation Myocardial Infarction (STEMI)

    phase 2 small molecule active

    1 trial

  16. RUBIDIUM CHLORIDE

    Pari Pharma GmbH

    Kidney carcinoma

    phase 2 small molecule active

    1 trial

  17. RX-3117

    Processa Pharmaceuticals

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  18. RX-3117

    Processa Pharmaceuticals

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  19. Ramipril

    Quantum Biopharma

    Myocardial Infarction

    phase 2 small molecule completed

    1 trial

  20. Randomized: 40 mg Paltusotine

    Crinetics Pharmaceuticals Europe GmbH

    Carcinoid Syndrome

    phase 2 small molecule completed

    1 trial

  21. Rapcabtagene autoleucel

    Novartis Pharmaceuticals

    ANCA Associated Vasculitis (AAV)

    phase 2 mab active

    1 trial

  22. Rasagiline

    Teva Pharma GmbH

    Dementia

    phase 2 small molecule completed

    1 trial

  23. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 2 small molecule active

    1 trial

  24. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources